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Abstract
Forced vital capacity (FVC), a spirometric measure of pulmonary function, reflects lung volume
and is used to diagnose and monitor lung diseases. We performed genome-wide association study
meta-analysis of FVC in 52,253 individuals from 26 studies and followed up the top associations
in 32,917 additional individuals of European ancestry. We found six new regions associated at
genome-wide significance (P < 5 × 10−8) with FVC in or near EFEMP1, BMP6, MIR-129-2/
HSD17B12, PRDM11, WWOX, and KCNJ2. Two (GSTCD and PTCH1) loci previously associated
with spirometric measures were related to FVC. Newly implicated regions were followed-up in
samples of African American, Korean, Chinese, and Hispanic individuals. We detected transcripts
for all six newly implicated genes in human lung tissue. The new loci may inform mechanisms
involved in lung development and pathogenesis of restrictive lung disease.
Introduction
Pulmonary function is a heritable trait that can be reliably measured by spirometry and
reflects the physiological state of the lungs and airways 1. Forced vital capacity (FVC), one
of the most widely used pulmonary function measures, approximates vital capacity. In
conjunction with forced expiratory volume in 1 second (FEV1), FVC is used to diagnose
various respiratory diseases. A reduced ratio of FEV1 to FVC (FEV1/FVC) indicates airflow
obstruction when FEV1 is reduced disproportionately relative to FVC. In contrast, a
decreased FVC in the face of a normal to elevated FEV1/FVC suggests a restrictive
ventilatory defect. In clinical practice, FVC is often used as a surrogate measure of disease
progression in patients with established restrictive lung disorders, such as idiopathic
pulmonary fibrosis 2,3. Reduced FVC is a strong predictor of mortality in the general
population, independently of FEV1 and standard risk factors such as age and cigarette
smoking 4–8.
Pulmonary function measures show familial aggregation, with evidence for genetic effects
in twin and family studies 9,10. We previously reported associations between FEV1 or
FEV1/FVC and at least 27 genetic loci using large-scale meta-analyses of genome-wide
association studies (GWAS) 11–14. To date, the genetic determinants of FVC have not been
studied using GWAS methods. We conducted a comprehensive GWAS meta-analysis across
two large consortia of European ancestry—the Cohorts for Heart and Aging Research in
Genomic Epidemiology (CHARGE) and SpiroMeta—to identify common genetic variants
associated with cross-sectional measures of FVC in 52,253 subjects of European descent. In
each of six new loci, we confirmed expression levels of genes nearest the novel variants in
lung tissue and performed expression quantitative trait locus (eQTL)-analyses in 762 whole
blood samples. We evaluated the new loci in 6,070 African Americans in the National Heart,
Lung and Blood Institute (NHLBI)-sponsored Candidate gene Association Resource (CARe)
Project, in a Chinese subset (n=563) of the Multi-Ethnic Study of Atherosclerosis (MESA),
in a Hispanic subset (n = 849) of MESA, and in Koreans (n = 8,074) from two cohort
studies; Healthy Twin 15–17 and Korea Association Resource 3 (KARE3) 18.
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Results
The study consisted of two stages. Stage 1 was a meta-analysis of study-specific genome-
wide analyses of FVC conducted in 26 studies with a total of 52,253 individuals of
European ancestry. The study characteristics are shown in Supplementary Table 1.
Individual cohorts performed a GWAS analysis using linear regression models with FVC (in
milliliters) as the outcome, stratified by never/ever smoking. Adjustment factors included
age, age2, sex, height, height2 and weight. If applicable, cohorts adjusted for center, cohort
or principal components to adjust for population stratification. Stage 1 results are in
Supplementary Data Set 1. In stage 2, we followed-up SNPs showing association with FVC
(P < 5 × 10−7) and meta-analyzed beta estimates and standard errors across stages 1 and 2
(Figure 1). Stage 2 encompassed 32,917 subjects of European ancestry from 9 independent
cohorts. The study characteristics are shown in Supplementary Table 2. The follow-up
studies used the same models. Effect estimates for each study were corrected using genomic
control 19 separately within smoking strata. Study-specific lambda estimates are shown in
Supplementary Table 1. The test statistic inflation (λGC) before applying genomic control at
the meta-analysis level was 1.12 (Supplementary Figure 1). The test statistic inflation
standardized for a sample size of 1,000 individuals was 1.002.
Regions around SNPs reaching genome-wide significance after the meta-analysis of the two
stages were followed up in diverse ancestry samples of African Americans, Koreans,
Chinese and Hispanics. The characteristics for these multi-ethnic follow-up studies are
shown in Supplementary Table 2. Following the meta-analysis, we investigated mRNA
expression of the nearest gene for each of the new SNPs in human lung tissue, human
airway smooth muscle cells (HASM), human bronchial epithelial cells (HEBC) and
peripheral mononuclear blood cells (PMBC) (Supplementary Note). We assessed whether
these SNPs were associated with gene expression in whole blood cells (Supplementary Note,
Supplementary Table 3) and queried databases to assess whether these SNPs are located
within known or predicted regulatory regions.
Stage 1 and 2 results
There were 9 regions containing at least one SNP associated with FVC at P < 5 × 10−7 in
stage 1. Of these, two (GSTCD and PTCH1) had previously been reported in GWAS12,13 of
spirometric traits (FEV1 and FEV1/FVC), thus were not evaluated further, leaving 7 SNPs in
7 loci for follow-up in stage 2.
Six loci reached genome-wide significance (P < 5 × 10−8) for FVC in the meta-analysis of
stages 1 and 2 (Table 1, Figure 2). The loci were in or near the following genes: BMP6
(rs6923462, 6p24, intronic), EFEMP1 (rs1430193, 2p16.1, intronic), MIR-129-2/HSD17B12
(rs4237643, 11p11.2, 54 kb upstream), PRDM11 (rs2863171, 11p11.2, 3 kb downstream),
WWOX (rs1079572, 16q23.1, intronic) and KCNJ2 (rs6501431, 17q24.3, 800 kb
downstream) (Supplementary Figures 2a–g). Effect sizes were generally consistent across
studies (Supplementary Figures 3 a–g and 4 a–g). Three of these regions (BMP6, EFEMP1
and PRDM11) also showed independent replication in stage 2 European ancestry samples,
with P values below a Bonferroni corrected threshold for 7 tests (P < 7.14 × 10−3) (Table 1).
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The lowest P value (5.89 × 10−13) for the meta-analyzed effect estimate across stage 1 and 2
was found for SNP rs6923462 (intronic SNP in BMP6).
We evaluated the effect of the six new loci separately in ever-smokers and in never-smokers,
and the effect sizes were consistent across smoking strata for all the variants (Supplementary
Table 4).
Multi-ethnic follow-up
To examine the portability of the identified loci to other ethnic groups, we evaluated the
regions of our newly identified SNPs in African Americans, Hispanics, Chinese, and
Koreans. For three of these samples (African Americans, Hispanics, and Chinese), we
looked up the SNPs with minor allele frequency (MAF) ≥ 0.05 within 200 kb in either
direction from the sentinel SNP in Europeans in the 1000 Genomes (1000G) Project all
ancestries imputation panel 20. For Koreans, we looked up the sentinel SNP +/− 200 kb for
SNPs with MAF ≥ 0.05 according to imputation to HapMap and the Korean panel. To
determine the appropriate Bonferroni-corrected P value threshold for declaring statistical
significance in each ethnic group, we used the Nyholt method to calculate the effective
number of independent variants, based on pairwise linkage disequilibrium among the
follow-up SNPs 21,22.
African Americans were participants of the Candidate gene Association Resource
consortium (CARe) 23. Baseline characteristics of the 6,070 African Americans in CARe are
shown by cohort in Supplementary Table 2b. We performed regional meta-analyses of the
7,470 SNPs (MAF ≥ 0.05) within +/− 200 kb of the sentinel SNPs in Europeans using
1000G imputed data. Using the P value threshold of 4.42 × 10−5 (based on 1,132
independent tests), 78 SNPs in the region of EFEMP1 were significantly associated with
FVC (lowest P = 1.63 × 10−7) in African Americans. Our top hit at the EFEMP1 locus in
European samples (SNP rs1430193, T allele frequency 0.37, Table 1) had a very different
allele frequency in our replication African American samples (T allele frequency 0.71) and
was not statistically significant (P = 0.13). As has been recently noted regarding extension
of GWAS SNPs discovered in Europeans to African-American populations 24, the effect
size was in the same direction but attenuated in our African-Americans (β = −15.79 ml
versus −23.75 ml). The top hit in African Americans for the EFEMP1 region (rs62164511, P
= 1.63 × 10−7) showed a decrease in FVC of 84.7 ml per each copy of the A-allele (A-allele
frequency: 0.9) (Supplementary Table 5a). The r2 between the most significant SNP
(rs62164511) in African Americans and the most significant SNP (rs1430193) in Europeans
was low (0.16), further supporting evidence for allelic heterogeneity at this locus
(Supplementary Figures 5a–b).
Baseline characteristics of the 563 Chinese subjects from MESA are shown in
Supplementary Table 2c. We performed regional analyses (+/− 200 kb, SNPs with MAF ≥
0.05) around the sentinel SNPs in Europeans using 1000 Genomes imputation. The P value
threshold was determined at 4.41 × 10−5 (based on 1,133 independent tests). None of the
7,436 investigated SNPs reached a statistical significance level below the predefined
threshold.
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Baseline characteristics of the 849 Hispanics from MESA are shown in Supplementary
Table 2d. We performed regional analyses of SNPs (MAF ≥ 0.05) within +/− 200 kb of the
sentinel SNPs in Europeans using 1000 Genomes imputation. None of the 7,473 investigated
SNPs reached a statistical significance level below the predefined threshold (4.41 × 10−5,
based on 1,133 independent tests).
Baseline characteristics of the 8,074 Koreans from the Healthy Twin 15–17 and KARE3 18
studies are shown in Supplementary Table 2e. In this sample, only HapMap imputed
(HapMap3 Phase 2 and Korean HapMap) data were available. There were 72 SNPs (MAF ≥
0.05) within +/− 200 Kb of the sentinel SNPs in Europeans. Using the threshold P value of
1.52 × 10−3 (based on 26 independent tests), two SNPs (rs12449659 and rs4793331, both
located approximately 700kb upstream of KCNJ2) were associated with FVC in Koreans
with a decrease of 32.5 ml (rs12449659, per T allele, P = 7.92 × 10−4) and 22.5 ml
(rs4793331, per A allele, P = 1.22 × 10−3). These SNPs did not show a significant
association with FVC in Europeans (P = 0.17 and P= 0.34, Supplementary Table 5b).
Gene set enrichment analysis
To identify plausible pathways associated with FVC, we broadened our focus beyond
genome-wide significant variants by performing gene set enrichment analysis 25 on the
entire meta-analyzed GWAS. We queried approximately 2,000 gene sets including
canonical pathways and Gene Ontology functional categories. Using a false discovery rate
(FDR) < 0.01, we identified 65 enriched pathways (Supplementary Table 6). While these
over-represented gene sets encompassed diverse functions, many involved processes critical
to organ development and tissue remodeling including epithelial morphogenesis, cell
proliferation, extracellular matrix, Notch signaling, and cell adhesion. Other prominent
pathways included acetylcholine binding and channel activity, smooth muscle contraction,
glutamate receptor activity, immunity, and transcriptional/DNA repair processes.
Gene expression
Expression profiles of genes from the six loci that were significant in the meta-analysis of
stages 1 and 2 (EFEMP1, BMP6, WWOX, KCNJ2, PRDM11 and HSD17B12), and the
housekeeping gene GAPDH, were measured in human lung tissue and primary cell samples
using RT-PCR. We detected transcripts for all six newly implicated genes in lung tissue,
human bronchial epithelial cells (HBEC) and human airway smooth muscle (HASM).
Transcripts for five of the 6 genes (excluding EFEMP1) were present in peripheral blood
mononuclear cells (PBMCs) (Table 2 and Supplementary Figures 6 and 7).
Expression quantitative trait locus analysis in peripheral blood cells
We investigated whether the top SNPs or their proxies (r2 ≥ 0.7) in the six newly implicated
FVC loci were associated with gene expression using expression Quantitative Trait Loci
(eQTL) data as described in the methods. Multiple SNPs in or near HSD17B12 showed
significant cis-eQTL associations (P < 10−4) in peripheral blood, with the strongest
association represented by rs11037676 (a proxy of rs4237643, r2 = 0.7) at a P value of 8.42
× 10−81 (Supplementary Table 3). The sentinel SNP associated with FVC in this region
(rs4237643) also exhibited a strong cis-effect on HSD17B12 (P = 1.82 × 10−35)
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(Supplementary Figure 8). Furthermore, this SNP showed a significant cis-eQTL association
in lymphoblastoid cell lines (P = 6.7 × 10−11) 26 and brain tissue (P = 1.2 × 10−8) 27.
Another FVC-associated SNP located in the intronic region of EFEMP1 (rs1430189)
demonstrated local effects on this gene’s expression based on eQTL data from human
fibroblasts (P = 4.8 × 10−6) 28. We did not find statistically significant cis-eQTLs for the
other FVC-associated variants and loci.
eQTL analysis in lung tissue
To better assess the relevance of cis-eQTLs to lung biology, we queried a publically
available database that included lung tissue (The Genotype-Tissue Expression project,
GTEx) 29 to further investigate the top SNPs and their proxies. Multiple SNPs mapped to
HSD17B12, including rs11037676 and the sentinel SNP, rs4237643, demonstrated highly
significant cis-eQTLs in human lung samples (P = 2.8 × 10−26 and P = 7.2 × 10−14,
respectively).
Fetal lung mRNA expression for genes associated with FVC
Studies were performed to investigate whether or not the genes we identified were
differentially expressed during normal human fetal lung development (Supplementary Table
7). There was strong evidence (P controlling for false discovery rate = 6.7 × 10−6) for
differential expression of PRDM11, suggesting this gene may play an important role in utero
in lung development. One probe for WWOX also showed correlation between lung
expression and fetal age although this was not seen with other probes for the gene.
Putative regulatory variants
We queried the RegulomeDB 30 database to assess whether any of the newly identified
FVC-associated SNPs (P < 10−7, n = 150 SNPs) were located within known or predicted
regulatory elements, including regions of DNAase hypersensitivity, binding sites of
transcription factors, and promoter regions that have been biochemically characterized to
regulate transcription. Five SNPs received high likelihood scores (based on the amount of
supporting data) for mapping to regulatory regions and affecting gene expression; these
were 4 variants upstream of HSD17B12 (rs9783304, rs2862996, rs10768966, and
rs6485443) and one variant downstream of EFEMP1 (rs1430189). These variants showed
evidence for eQTL, transcription factor binding and/or DNase peak.
Discussion
In a two-stage meta-analysis across 35 cohorts encompassing 85,170 individuals of
European ancestry, we found 6 new loci associated with FVC that had not been identified in
previous GWAS of spirometric measures of airflow obstruction (FEV1 or FEV1/FVC). The
six new loci showed consistent associations across the European ancestry studies in
discovery and replication stages. The meta-analysis effect estimates range from 13 to 31 ml
per allele, which is similar to the annual rate of decline of FVC ranging from 12 to 47 ml in
the general population 31. Expression analyses showed that all the top candidate genes at
these loci were expressed in lung tissue and primary lung cells (HBEC and HASM). Two
additional loci associated with FVC at genome-wide significance in the stage 1 analysis
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were previously associated with FEV1/FVC (PTCH1) or FEV1 (GSTCD) 12–14 at genome-
wide levels of significance in GWAS.
The six new associations found in this analysis explain only a modest proportion of the
additive polygenic variance of FVC (0.74%). Stage 2 effect size estimates were used to
calculate the proportion of the variance explained by the six new loci, to avoid the effect of
winner’s curse bias. When we take the other known loci for pulmonary function into
account, the proportion of the additive polygenic variance explained is 1.78%, a finding that
is comparable to many other complex traits 32. Unexplained heritability has become a well-
known phenomenon in genetic epidemiology 33 and possible explanations include multiple
effects of common variants, rare variants, gene-by-environment interactions, gene-gene
interactions and epigenetic regulation - mechanisms that are not captured by existing GWAS
platforms.
We, and others, previously identified 27 regions associated at genome wide significance
with FEV1, FEV1/FVC or both 11–14. Although FEV1 and FVC are statistically correlated (r
= 0.83 in the Rotterdam Study, adjusted for age, sex, height and height2), these are clinically
different entities. FVC is used for the evaluation of restrictive ventilatory defects and is a
predictor of mortality independent of FEV1, standard risk factors, and even prior
cardiovascular disease 5,6. In contrast, FVC and FEV1/FVC have a very low correlation (r =
−0.08 in the Rotterdam Study, adjusted for age, sex, height and height2). In this analysis, we
were able to identify 6 new loci that are associated with FVC at genome-wide significance.
Only two of the loci that were previously associated with FEV1 or FEV1/FVC showed
genome-wide significant association with FVC in our study (GSTCD and PTCH1) 12,13. The
sentinel SNPs at each of the six novel loci showed consistent directions of effect on both
FEV1 and FVC (Supplementary Table 8). Among our FVC-associated SNPs, the smallest P
value for FEV1 (9.43 × 10−7) was observed for rs1079572 (WWOX). An intragenic SNP
(rs11654749) in the region between KCNJ2 and SOX9 was associated with FEV1 at genome-
wide significance in our previous meta-analysis of SNP and SNP-by-smoking effects 34. To
assess whether the variant (rs11654749) identified in that analysis of FEV1 and the sentinel
SNP (rs6501431) from our current FVC analysis are pointing to the same signal, we fitted
both variants together in the model using the software GCTA 35. Their effects sizes
increased slightly when fitted together as expected given that the marginal correlation
(r=0.03) of their alleles was positive and the effects of these alleles on lung function were in
opposite directions. Thus, these SNPs appear to be independent signals.
Two of the top loci for FVC (BMP6 and EFEMP1) have been associated with height in a
previous GWAS 36. The FVC-associated SNPs in or near these two genes show a modest to
weak correlation with the top SNPs from the height GWAS 36. For EFEMP1, the r2 between
rs1430193 (for FVC) and rs3791675 (for height) was 0.45. For BMP6, the correlation
between rs6923462 (for FVC) and two SNPs associated with height (rs3812163 and
rs1219896) was low. For rs6923462 and rs3812163, the r2 was 0.01 and for rs6923462 and
rs1219896 the r2 was 0.02. Since we adjusted for height in our analysis, our findings are
likely to be independent of height, but may reflect genetic effects on body or organ size.
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To assess whether our identified loci are associated with FVC across populations of different
ancestries, we assessed the associations of our main findings in African Americans,
Koreans, Hispanics, and Chinese subjects. Despite the limited size of these samples, 78
SNPs in the region of EFEMP1 reached the significance threshold of P < 4.42 × 10−5 in
African Americans. These results support the involvement of this locus in lung function in
individuals of both European and African descent, although there was evidence for allelic
heterogeneity. In the Korean dataset, we found two SNPs in the region of our locus near
KCNJ2 (LOC101928165) to be significantly associated with FVC. In the smaller samples of
Chinese and Hispanic participants, none of the investigated SNPs were significantly
associated with FVC which may not be surprising given the greatly reduced power. In
summary, despite the smaller sample size, we were able to show significant evidence of
association with FVC for the EFEMP1 locus in African Americans and for the locus
downstream of KCNJ2 in Koreans.
A literature review identified candidate genes within the newly identified associated loci
plausibly involved in lung growth and pathogenesis. For example, BMP6 is a member of the
bone morphogenetic proteins (BMPs) that represent a key canonical signaling pathway in
the regulation of lung development, repair and response to injury 37. BMP6 expression in
bronchial epithelial cells has been reported to increase during experimental models of
allergic airway inflammation 38. EFEMP1 is part of the fibulin family of extracellular matrix
glycoproteins and encodes fibulin-3. Targeted disruption of a member of this -family,
fibulin-4, has been shown to cause reduced elasticity and emphysematous morphology in the
lungs of mice 39. Expression of other members of the fibulin family (fibulin-1 and fibulin-5)
seems to be influenced by transforming growth factor beta 1 (TGF-β1), a gene previously
linked to inflammation in COPD patients 40,41. WWOX may influence protein-induced
apoptosis and behaves as a tumor suppressing gene in various types of neoplasms, including
small cell lung cancer 42. Our analysis in fetal lung data showed strong evidence for
differential expression of PRDM11 suggesting a role in in utero development. In addition,
nuclear expression of PRDM11 has been shown in respiratory epithelial cells of the human
bronchus in 3 subjects Human Protein Atlas 43. Interestingly, our eQTL-analysis revealed
highly significant cis-effects of FVC-associated variants on HSD17B12 expression in
multiple tissues including lung. Furthermore, several of these SNPs were located within
regulatory sites upstream of HSD17B12, suggesting that these variants may play a regulatory
role in gene function. Exploratory pathway analysis using the all SNPs in the meta-analysis
of FVC implicated multiple processes, including several involved in tissue development and
remodeling. These findings suggest that distinct and identifiable biological pathways
underlie the genetic basis of lung’s vital capacity in the general population.
There are some limitations of our analysis. With cross-sectional measures of FVC, we
cannot determine whether the identified signals are due to influence on lung growth or age-
related lung function decline 44. The primary analyses were not adjusted for pack-years to
avoid attrition in sample size, but within the CHARGE cohorts, estimates from meta-
analysis with and without adjustment for pack years were very similar (results not shown).
An important strength of our study is its considerable sample size of European ancestry
individuals. Our application of genomic control at the three stages is likely to be overly
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conservative because it has recently been shown that in large meta-analyses, test statistics
are expected to be elevated under polygenic inheritance even when there is no population
structure. Genomic inflation estimates increase with sample size, as has been shown for
other traits 14,36,45,46. Following the two staged meta-analysis, we were able to test the SNPs
and their regions for tissue specific expression.
In conclusion, using a large-scale staged meta-analysis, we report six new loci associated
with FVC and show that all are expressed in lung tissue and primary lung cells. Our findings
point to previously unexplored pathways and mechanisms underlying lung function.
Improvement of the understanding of the role that these genes play in normal lung
development and disease pathogenesis could lead to novel therapeutic targets for lung
diseases.
Online Methods
Study design
The study consisted of two stages. Stage 1 was a meta-analysis of study-specific genome-
wide analyses of FVC conducted in 26 studies with a total of 52,253 individuals of
European ancestry. The study characteristics are shown in Supplementary table 1. In stage 2,
we followed-up SNPs showing association with FVC (P < 5 × 10−7) and meta-analyzed
betas and standard errors across stages 1 and 2. Stage 2 encompassed 32,917 subjects of
European ancestry from 9 independent cohorts.
Cohorts included in stage 1
Stage 1 included a total of 26 studies, 15 from the SpiroMeta consortium and 11 from the
CHARGE consortium: AGES, ARIC, B58C T1DGC, B58C WTCCC, CARDIA, CHS,
ECRHS, EPIC (obese cases and population-based studies), the EUROSPAN studies
(CROATIA-Korcula, ORCADES, CROATIA-Vis and NSPHS), FHS, FTC (incorporating
the FinnTwin16 and Finnish Twin Study on Aging), Health 2000, Health ABC, HCS,
KORA S3, MESA, NFBC 1966, RS-I, RS-II, RS-III, SHIP and Twins UK-I. The
genotyping platforms and quality-control criteria implemented by each study are described
in Supplementary Table 9.
Cohorts included in stage 2
A total of 9 studies were included in our stage 2 follow-up: BHS 1 & 2, CROATIA-Split,
Generation Scotland, KORA F4, LBC1936, LifeLines, LLFS, Pivus, Twins UK-II & III.
Study descriptions can be found in the Supplementary Note.
Imputation
Imputation to the HapMap CEU panel was conducted using either MACH 47, IMPUTE 48,
Beagle 49,50 or BIMBAM 51 with filters and quality control parameters as shown in
Supplementary Table 9. SNPs were excluded on a cohort basis if the imputation score,
assessed using r2.hat (MACH), .info (IMPUTE) or OEvar (BIMBAM), was < 0.3. In total,
2,762,059 SNPs were analyzed.
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Statistical analysis
Individual studies performed a GWAS analysis using linear regression models with FVC (in
milliliters) as the outcome, stratified by never/ever smoking. Adjustment factors were age,
age2, sex and height (plus height2 and weight for CHARGE and replication cohorts). If
applicable, cohorts adjusted for center, cohort or principal components to adjust for
population stratification. The follow-up studies used the same models. Effect estimates for
each study were corrected using genomic control 19 separately within smoking strata. Study-
specific lambda estimates are shown in Supplementary Table 1.
Meta-analysis of stage 1 data
Variants with imputation quality below 0.3 or minor allele frequency below 0.03 were
excluded from each dataset before the meta-analysis. Study-specific effect estimates and
standard errors for ever-smokers and never-smokers were combined using METAL 52 with
fixed-effects inverse variance weighted meta-analysis, which takes directionality into
account by aligning study results according to the same effect allele. Genomic control was
applied to the resulting combined (ever-smokers and never-smokers) effect estimates for
each study. These combined effect estimates for each study were then combined across
studies, again using fixed-effect inverse variance weighted meta-analysis with METAL, and
genomic control was applied again to the final meta-analysis estimates. Manhattan plots,
quantile-quantile-plots, forest-plots, gene annotation, and additional statistics were produced
using R version 2.9.2 53. Stage 1 results are in Supplementary Data Set 1.
Selection of SNPs for stage 2 and stage 2 meta-analysis
For every region containing at least one SNP showing evidence for association with FVC (P
< 5 × 10−7), the SNP with the smallest P value that also had a N effective ≥ 80% (the N
effective is the product of sample size and the imputation quality summed across studies) of
the total stage 1 sample size was followed up in a second stage using in silico data from 9
cohorts (Figure 1, Supplementary Table 2a). In total, 7 SNPs were followed up. Results for
variants with imputation quality (Supplementary Table 10) below 0.3 in a given study were
excluded from the meta-analysis. Results across stage 2 studies were meta-analyzed using
fixed-effects inverse variance weighted meta-analysis with METAL 52.
Regions were defined as independent if the leading SNP from one region was > 500
kilobases (kb) from the leading SNP of any other region. We excluded two regions (GSTCD
and PTCH1) from follow-up, that were previously associated with FEV1 or FEV1/
FVC 12–14.
Combined analysis of stage 1 and stage 2
We performed an inverse variance weighted fixed effects meta-analysis across stages 1 and
2 using METAL 52 and obtained two-sided P values for the resulting effect estimates.
Follow-up in other ethnicities
To evaluate these loci across ethnicities, we studied association with FVC in four samples of
non-European ancestry. We used data from the National Heart, Lung, and Blood Institute
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(NHLBI)-sponsored Candidate gene Association Resource (CARe) Project 23,54, which
genotyped African Americans in ARIC, MESA, CHS, CARDIA, the Jackson Heart Study
and the Cleveland Family Studies. The analyses in CARe were carried out per cohort and
meta-analyzed using METAL 52. Furthermore, we assessed the SNPs in Hispanic and
Chinese participants from the MESA study. Lastly, we investigated the loci in Korean
participants from the Healthy Twin 15–17 and KARE3 18 studies. For the Korean studies, the
analyses were carried out per cohort and meta-analyzed. Individual studies performed a
GWAS analysis using linear regression models with FVC (in milliliters) as the outcome.
Adjustment factors were age, age2, sex, height, height2, ever/never smoking and weight. We
assessed the sentinel SNPs from the HapMap CEU reference panel that were available and
SNPs from the regions of the identified loci based on location of the sentinel SNPs ± 200 kb.
Only SNPs with a MAF ≥ 0.05 were included. The estimated number of independent tests
per population sample and corresponding Bonferroni P values are shown in Supplementary
Table 11. The effective number of independent variants being tested in each replication
population was estimated based on linkage disequilibrium between SNPs using the
technique of Li and Ji 22, which is a modification of the technique originally proposed by
Cheverud 55 and implemented by Nyholt 21. This calculation was performed using
“matSpD” 21 based on the linkage disequilibrium structures of the 1,000 Genomes “all
ancestries” sample.
Gene set enrichment analysis
We applied an algorithm known as improved gene set enrichment analysis for GWAS (i-
GSEA4GWAS) to place variants associated with FVC within curated pathways and
functional categories 25. SNPs from the stage 1 and 2 meta-analyzed GWAS were mapped
to genes if within a 100 kb distance (upstream or downstream). For a given SNP, if multiple
genes were located within this range, the closest gene was selected and assigned the
association P value. Since multiple SNPs can map to the same gene, a SNP label
permutation was used to reduce biases caused by larger loci having disproportionately
higher number of SNPs. Log-transformed association P values were used to rank order the
resulting gene list (18,454 genes) and calculate gene set enrichment scores. Approximately
2,000 gene sets were used. These were limited to curated pathways derived from multiple
resources such as KEGG, BioCarta, REACTOME, and functional annotations extracted
from the Gene Ontology database. A modified version of GSEA procedure was performed
and adjusted for multiple testing using false discovery rate (FDR). Significant enrichment of
gene sets was set at FDR < 0.01.
Gene expression analysis
Following the meta-analysis, we investigated mRNA expression of the nearest gene for each
of the new SNPs in: human lung tissue, human airway smooth muscle cells (HASM), human
bronchial epithelial cells (HEBC) and peripheral mononuclear blood cells (PMBC). Lung
resection specimens were obtained from patients diagnosed with solitary pulmonary tumors
at Ghent University Hospital (Ghent, Belgium). Primary human bronchial epithelial cells
(HBEC) and human airway smooth muscle cells (HASM) were prepared from lung resection
specimens obtained from anonymous donors during surgery for lung cancer at the Leiden
University Medical Center (LUMC, Leiden, The Netherlands). All assays were done at the
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Ghent University Hospital. Peripheral blood mononuclear cells (PBMCs) were isolated from
whole blood using Ficoll gradients. Written informed consent was obtained from all subjects
according to protocols approved by the local ethics committees. Total RNA was extracted
from samples using the miRNeasy Mini kit (Qiagen) and cDNA was prepared from 1µg
RNA template using the Transcriptor Universal cDNA Master kit (Roche) following
manufacturer’s instructions. Expression of the candidate genes and the housekeeping gene
GADPH was analyzed using TaqMan Gene Expression Assays (Applied Biosystems, Forster
City, CA, USA; Assay ID numbers are given in Supplementary Table 12 in the
Supplementary Note).
Expression Quantitative Trait Loci
We assessed whether top SNPs or their proxies, based on an r2 > 0.7, in the six new regions
were associated with gene expression in whole blood cells in a sample of 762 individuals
from the Rotterdam Study III (RS-III)56. Expression was assessed using Illumina Whole-
Genome Expression Beadchips (HumanHT-12 v4). For eQTL-analysis, we used the eQTL
mapping pipeline called MegaQTL 57. eQTLs were deemed cis when the distance between
the SNP chromosomal position and the probe midpoint was less than 250 kb. eQTLs were
mapped using Spearman’s rank correlation, using the imputation dosage values as
genotypes. Resultant correlations were then converted to P values and their respective z-
scores weighted with the square root of the sample size. The model was adjusted for the first
40 eigenvectors of the principal component analysis. We corrected for multiple testing by
using Bonferroni correction: associations with P < 10−4 were considered statistically
significant.
Finally, we also queried publicly available eQTL databases derived from multiple cell and
tissue types (lymphoblastoid cell lines, brain tissue and human fibroblasts) 26–29. We
corrected for multiple testing by using Bonferroni correction: associations with P < 10−4
were considered statistically significant.
Expression in fetal lung
We used methods previously described 58 to mine publicly available data 59,60 to identify
whether differential expression of relevant genes occurs during normal human lung
development. Previously, human fetal lung tissues were obtained from National Institute of
Child Health and Human Development tissue databases and microarray profiles used to
investigate the expression spanning different gestational ages. RNA samples from 38
subjects (estimated gestational age 7–22 weeks or 53–154 days post conception)
representing the pseudoglandular (gestational age, 7–16 weeks) and canalicular (17–26
weeks) stages of lung development were included within the dataset. These data are
available at NCBI Gene Expression Omnibus.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Study design
Overview of our staged analysis to identify new variants influencing FVC. After a large-
scale meta-analyzed GWAS of stage 1 cohorts (n = 52,253), we followed-up a total of 7
SNPs showing evidence of association with FVC (P < 5 × 10−7) in stage 2. The studies
included in stage 2, encompassing a total sample size of n = 32,917, undertook in silico
testing of the 7 loci, which were not previously associated to any pulmonary phenotype. See
Supplementary Tables 1 and 2 for definitions of all study abbreviations
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Figure 2. Manhattan plot
Manhattan plot for the association results for FVC. The plot shows all the loci analyzed in
stage 1, where the two loci previously associated with either FEV1 or FEV1/FVC are
indicated in grey. The previously unassociated loci were in or near the presented adjacent
gene. The loci reaching genome-wide significance, after the combined analysis of stage 1
and stage 2, are marked with an asterisk.
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 ro
le
 in
 th
e
re
gu
la
tio
n 
of
 a
 w
id
e
v
ar
ie
ty
 o
f c
el
lu
la
r
fu
nc
tio
ns
 su
ch
 a
s p
ro
te
in
de
gr
ad
at
io
n,
tr
an
sc
rip
tio
n,
 a
nd
 R
N
A
sp
lic
in
g.
 T
hi
s g
en
e
en
co
de
s a
 p
ro
te
in
 w
hi
ch
co
n
ta
in
s 2
 W
W
 d
om
ai
ns
an
d 
a 
sh
or
t-c
ha
in
de
hy
dr
og
en
as
e/
re
du
ct
as
e
do
m
ai
n 
(S
RD
).
+
+
+
+
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Ti
ss
ue
Se
nt
in
el
 S
N
P
(re
lat
ion
sh
ip
to
 g
en
e)
C
hr
.
G
en
e
Pu
ta
tiv
e 
fu
nc
tio
n 
of
en
co
de
d 
pr
ot
ei
n
Lu
ng
H
A
SM
H
BE
C
PB
M
C
rs
65
01
43
1
(do
wn
str
ea
m)
17
K
CN
J2
Th
e 
pr
ot
ei
n 
en
co
de
d 
by
th
is 
ge
ne
 is
 a
n 
in
te
gr
al
m
em
br
an
e 
pr
ot
ei
n 
an
d
in
w
ar
d-
re
ct
ifi
er
 ty
pe
po
ta
ss
iu
m
 c
ha
nn
el
. T
he
en
co
de
d 
pr
ot
ei
n,
 w
hi
ch
ha
s a
 g
re
at
er
 te
nd
en
cy
 to
al
lo
w
 p
ot
as
siu
m
 to
 fl
ow
in
to
 a
 c
el
l r
at
he
r t
ha
n 
ou
t
o
f a
 c
el
l, 
pr
ob
ab
ly
pa
rti
ci
pa
te
s i
n
es
ta
bl
ish
in
g 
ac
tio
n
po
te
nt
ia
l w
av
ef
or
m
 a
nd
ex
ci
ta
bi
lit
y 
of
 n
eu
ro
na
l
an
d 
m
us
cl
e 
tis
su
es
.
+
+
+
+
+
 in
di
ca
te
s t
ha
t t
he
 g
en
e 
is 
ex
pr
es
se
d 
in
 th
e 
ce
ll 
ty
pe
 u
se
d,
 a
nd
 −
 in
di
ca
te
s t
ha
t w
e 
di
d 
no
t d
et
ec
t g
en
e 
ex
pr
es
sio
n 
at
 th
e 
m
RN
A
 le
ve
l f
ol
lo
w
in
g 
70
 c
yc
le
s o
f P
CR
. A
m
pl
ifi
ca
tio
n 
w
as
 fo
llo
w
ed
 in
 re
al
-ti
m
e 
by
ge
ne
 sp
ec
ifi
c 
Ta
qM
an
 p
ro
be
s a
nd
 fi
na
l P
CR
 p
ro
du
ct
s w
er
e 
vi
su
al
iz
ed
 b
y 
ge
l e
le
ct
ro
ph
or
es
is.
 W
e 
us
ed
 G
AP
D
H
 
(en
co
din
g g
lyc
era
lde
hy
de
-3-
ph
os
ph
ate
 de
hy
dro
ge
na
se)
 as
 a 
po
sit
ive
 co
ntr
ol 
for
 th
e
co
m
pl
em
en
ta
ry
 D
N
A
, a
nd
 th
is 
ge
ne
 w
as
 e
xp
re
ss
ed
 in
 a
ll 
tis
su
es
. C
hr
., 
ch
ro
m
os
om
e;
 H
A
SM
, h
um
an
 a
irw
ay
 sm
oo
th
 m
us
cl
e;
 H
BE
C,
 h
um
an
 b
ro
nc
hi
al
 e
pi
th
el
ia
l c
el
ls;
 P
BM
C,
 p
er
ip
he
ra
l b
lo
od
 m
on
on
uc
le
ar
ce
lls
.
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